Walden University

ScholarWorks
Walden Dissertations and Doctoral Studies

Walden Dissertations and Doctoral Studies
Collection

2019

Reducing Antipsychotic Medication Use in LongTerm Care Settings
Martha Ofeibea Agbeli
Walden University

Follow this and additional works at: https://scholarworks.waldenu.edu/dissertations
Part of the Family, Life Course, and Society Commons, Nursing Commons, and the Psychiatric
and Mental Health Commons
This Dissertation is brought to you for free and open access by the Walden Dissertations and Doctoral Studies Collection at ScholarWorks. It has been
accepted for inclusion in Walden Dissertations and Doctoral Studies by an authorized administrator of ScholarWorks. For more information, please
contact ScholarWorks@waldenu.edu.

Walden University
College of Health Sciences

This is to certify that the doctoral study by

Martha Agbeli

has been found to be complete and satisfactory in all respects,
and that any and all revisions required by
the review committee have been made.

Review Committee
Dr. Barbara Niedz, Committee Chairperson, Nursing Faculty
Dr. Rosaline Olade, Committee Member, Nursing Faculty
Dr. Joan Hahn, University Reviewer, Nursing Faculty

The Office of the Provost

Walden University
2019

Abstract
Reducing Antipsychotic Medication Use in Long-Term Care Settings
by
Martha Ofeibea Agbeli

MS, Drexel University, 2015
BS, University of Rhode Island, 2009

Project Submitted in Partial Fulfillment
of the Requirements for the Degree of
Doctor of Nursing Practice

Walden University
November 2019

Abstract
The prescription rate of antipsychotics in patients with dementia varies between 20% and 50%
for the common and troubling neuropsychiatric symptoms experienced by patients with
dementia. The use of these antipsychotic medications has been linked with increased risk of
morbidity and mortality due to associated Parkinsonism, over sedation, gait disturbances,
cognitive decline, and cardiovascular adverse events. The purpose of this project was to assess
whether development of an evidence-based clinical practice guideline (CPG) for a long-term care
facility would increase awareness about issues that govern the safe use of antipsychotic
medications. The conceptual framework for the project was Watson’s model of caring. The
Fineout-Overholt tool was used to rank and score information retrieved following an extensive
literature review. An expert panel made up of 2 medical doctors and 4 nurse practitioners had
100% agreement that objectives were clear; content was relevant and easy to understand; the
CPG was well-organized and easy to follow; and knowledge learned would be used in practice.
From 66.6% to 83.3% agreed that the CGP led to an improved understanding of dementia,
neuropsychiatric symptoms, medication adverse events, and nonpharmacologic interventions.
The expert panel agreed to launch the CPG upon implementation of an educational program for
frontline nursing staff and a behavioral log to track occurrence and frequency of behaviors and
the use of nonpharmacologic interventions and their effectiveness in managing behaviors. Safe
implementation of this CPG might be adapted to other long-term facilities to optimize dementia
care, which would bring about a positive social change.
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Section 1: Nature of the Project
Introduction
Larson (2018) defined dementia as an overall decline in cognition related to one
or more of the cognitive domains, namely, learning and memory, language, executive
function, complex attention, perceptual-motor, and/or social cognition. According to
Press and Alexander (2017), neuropsychiatric symptoms of dementia are very common
and much more troubling than the amnestic symptoms. These neuropsychiatric symptoms
include agitation, aggression, delusions (particularly paranoid delusions), hallucinations,
wandering, depression, apathy, disinhibition, anxiety, irritability, and sleep disturbances
(Press & Alexander, 2017). According to Sahin Cankurtaran (2014), 97% of dementia
patients develop behavioral and psychiatric symptoms during the disease.
For many years practitioners and prescribers alike have used antipsychotic
medication as first-line agents for managing nursing home patients who exhibit behaviors
such as agitation, aggression, and psychotic symptoms of delusions and hallucinations
(Lindsey, 2009). The use of antipsychotics is even more prevalent among patients with
dementia who exhibit neuropsychiatric symptoms associated with the disorder. Jeste and
Maglione (2013) reported that prescription rates for antipsychotics in dementia range
from 20% to 50%. These medications are often used to treat the distress associated with
psychotic symptoms in this population; however, their use for the dementia patient
population is considered off-label and not approved by the Food and Drug Administration
(FDA; Madhusoodanan & Ting, 2014). Over time, the use of these medications has been
associated with increased morbidity and mortality as well as several other adverse effects
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(Saltz, Robinson & Woerner, 2004). Prescribers lack the knowledge governing the use of
these medications and the current guidelines that are available to help reduce the
prescriptions of such medications.
The purpose of this evidence-based project was to develop a clinical practice
guideline (CPG) that aimed at raising awareness about current issues governing the use of
antipsychotic medications in dementia patients. This CPG, ensuring that practitioners and
prescribers adhere to evidence-based practice on the use of pharmacological psychotropic
management for patients with dementia, represents a positive social change. Prompting
prescribers to pay closer attention to antipsychotic medication use is paramount, safer for
the patient, and is a mark of compliance with state and federal regulations.
Problem Statement
According to Bartels (2011), 68% to 91% of residents in long-term care facilities
have some type of mental disorder with most of these patients (i.e. 70-80%) having an
additional diagnosis of dementia. Though antipsychotic medications have commonly
been used as first-line agents, it should be noted that the FDA has not approved this class
of medications for the management of psychosis, agitation, and other neuropsychiatric
symptoms in patients with dementia (Tampi, Tampi, Balachandran, & Srinivasan, 2016).
In fact, antipsychotic use in patients with dementia has been linked to serious adverse
effects such as the increased risk of death, severe cerebrovascular adverse events
(CVAEs), and other serious side effects (Tampi et al. 2016). In 2008 the FDA issued a
strong warning which identified the link between antipsychotic medications and
increased mortality risk in elderly patients with dementia (De Jong, Van der Elst &
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Hartholt, 2013). This makes it particularly challenging in patients with a pre-existing
mental illness who develop dementia as they age in the nursing home setting as many of
these patients have been properly prescribed antipsychotics for many years.
Over the past decade many organizations such as the Centers for Medicare and
Medicaid (CMS), the American Health Care Association (AHCA), and The Omnibus
Budget Reconciliation Act (OBRA) regulations, among others, have guided steps by
health care providers to limit the prescribed use of antipsychotic medication for residents
of long-term care nursing facilities (Centers for Medicare and Medicaid, 2013). Other
organizations, such as the American Psychiatric Association, have developed clear
practice guidelines on the use of antipsychotics in the treatment of agitation and
psychosis among dementia patients (Centers for Medicare and Medicaid, 2013). These
guidelines call for practitioners and prescribers to focus on the assessment of
behavioral/psychologic symptoms of dementia, the development of comprehensive
treatment plans, assessment of benefits and risks of antipsychotic treatment for patients,
and focus on dosing, duration, and monitoring of antipsychotic treatment (Saltz,
Robinson, and Woerner, 2004).
In today’s healthcare sector, many providers prescribe medications such as
antipsychotics for patients without adequate knowledge of current guidelines governing
the use of these medications. Antipsychotic medications are often prescribed for
symptoms such as delusions, depression, and agitation associated with dementia (Jeste
and Maglione, 2013). According to Saltz, Robinson, and Woerner (2004), these
medications are misused because conditions such as delirium and dementia often mask
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depression, anxiety, and other mental illnesses to the inexperienced observer. The
Psychological Outcome Severity Guide, which was issued by the CMS in 2006, provides
criteria for surveyors of nursing facilities in the determination of correct levels of
negative psychosocial outcomes as a means of assessing the appropriateness of
prescribing antipsychotic medications (Centers for Medicare & Medicaid, 2016).
Under the Unnecessary Drugs section of this guide, CMS outlined the importance
of comprehensive assessments of residents in a nursing home to ensure that each
resident’s drug regimen is free of unnecessary drugs (Centers for Medicare & Medicaid,
2016). The CMS urged nursing home facilities not to use antipsychotic drugs for patients
who are not already taking them unless it is necessary to treat specific conditions (Centers
for Medicare and Medicaid, 2016). These must be diagnosed and documented in the
clinical record (Centers for Medicare and Medicaid, 2016). According to the Centers for
Medicare & Medicaid (2016), residents already using antipsychotic medications must
receive a gradual reduction in dose and behavioral interventions unless there is clear
clinical evidence pointing to a contraindication. This is encouraged in an effort to
discontinue antipsychotic medications. CMS defines gradual dose reduction (GDR) as a
slow, step by step, dose tapering to determine if the patient can be safely managed by
lowering dose or determining whether or not the medication can be discontinued (Centers
for Medicare & Medicaid, 2016).
According to Saltz et al. (2004), the lack of psychopharmacologic training is
evident in practitioners who misuse antipsychotic medications. Many providers and
prescribers lack training in the use of antipsychotic agents. I conducted the presentation
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of the CPG to an expert panel of six prescribers who work in a 250-bed long-term care
facility located in the northeastern part of the United States. The significance of this
problem to this setting is that the facility has a designated 60-bed locked psychiatric unit
and a 25-bed dementia unit. Residents who reside in the locked psychiatric unit have a
primary diagnosis of a psychiatric disorder (i.e. schizophrenia, schizoaffective disorder,
bipolar disorder) and are prescribed one or more antipsychotic medications. The patients
on the dementia unit have either a primary diagnosis of dementia or a psychiatric disorder
with a secondary dementia diagnosis. Some of the patients on the dementia unit are either
prescribed antipsychotic medication for their primary psychiatric disorder or for
behavioral disturbances associated with dementia.
The significance of this project for nursing practice is to reduce the prescription of
psychotropic medications for the management of behaviors associated with dementia.
The objective of this project was to highlight the use of nonpharmacologic interventions
and intensive staff education programs as alternatives to addressing behavioral
disturbances. Developing clear CPGs on the use of, monitoring, and the need for ongoing
assessments of antipsychotic medications will help raise awareness about this class of
medications.
Purpose Statement
As mentioned by Wolf, Grol, Hutchinson, Eccles, and Srinivasan (2016), the
principal benefit of practice guidelines is to promote evidence-based interventions while
discouraging ineffective ones with the goal of reducing morbidity and mortality while
improving the overall quality of life. The purpose of this project was focused on
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establishing a clear CPG for prescribers in a nursing home setting. The CPG was based
on current evidence from nursing and related research and the Centers for Medicare and
Medicaid, as well as the American Psychiatric Association, and addressed the principal
gap in the prescriber practice at the long-term care setting.
In this setting antipsychotics are still being used routinely in patients with a
diagnosis of dementia to control assertive or aggressive behaviors. The patient population
is a complex one, as most of these patients have a comorbid mental illness, for which the
use of antipsychotics is appropriate. Many of these patients are long-term mental illness
patients who develop symptoms of dementia after years of treatment with antipsychotics.
The CMS (2016) recommended a titrated approach which is an antipsychotic reduction
plan for these patients. However, these protocols are not in use at the DNP setting. The
current practice of prescribing antipsychotics for the dementia patient population
represents the primary gap in practice at the DNP project setting that the practice
guideline is intended to address. The hypothesis was that a CPG on the use of
antipsychotic medications will potentially impact each prescriber’s knowledge base and
provide insight on the current evidence-based practice as well as the state and federal
guidelines on psychotropic medication prescribing and management of patients in the
long-term care setting. Thus, the practice-focused question that guides the DNP project
is: Will an expert panel approve the use of a CPG on the use of antipsychotic medication
in the nursing home setting?
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Nature of the Doctoral Project
This doctoral project focused on the development of a CPG for prescribers and
practitioners who care for patients with dementia in long-term care. The approach to this
project was guided by the Walden CPG Manual. Evidence was collected from many
sources, primarily, the CMS regulations and the research evidence on the appropriate use
of antipsychotics in the elderly dementia patient with and without a history of comorbid
psychosis. These sources of published evidence were used to develop the clinical practice
guideline, and it was guided by Watson’s model of caring (Watson Caring Science
Institute, 2010). In addition, the Agree II model for the development practice guidelines
provided a methodological framework, as noted in the Walden CPG manual. The
Fineout-Overholt tool (2010) was used to grade the evidence which is presented in a
literature matrix.
The CPG was presented to an expert panel made up of four nurse practitioners
(NPs) and two physicians (MDs) for review, recommendations, identification of
anticipated barriers to full implementation, and to potentially gain consensus on their
willingness to accept the CPG for use in the behavioral health long term care setting
where they are employed. As prescribers for the aging population, medical professionals
must not only advocate for patients but also be prudent when prescribing antipsychotic
medications. The overall goal was to help raise awareness on the current evidence to
close the gap-in-practice at the DNP project site as well as complying with the governing
state and federal regulations for prescribing this class of medications in the nursing home
setting.
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Presenting the CPG to an expert panel raised awareness of existing
recommendations governing these medications and allowed for formative evaluation in
the development of the CPG. The goal was that nurse practitioners and other providers at
the site would become more knowledgeable about the current research evidence and
regulations pertaining to the use of antipsychotics. A continuation of the goal is for the
prescribers to focus on the importance of ongoing assessments; document indication for
medications, monitor for side effects, and consider gradual dose reductions and
discontinuation when necessary.
Significance
This project was significant to the nursing home facility, prescribers, and
practitioners as there were no current guidelines outlining the prescription and use of
antipsychotic medications. The development and presentation of a CPG such as this
provide an opportunity for prescribers and practitioners to be exposed to the latest
evidence surrounding the use of antipsychotic medications in the nursing home setting.
With this CPG, prescribers and practitioners indicated an increase in their knowledge
base and gain insight on antipsychotic medications, when to prescribe them and the
associated adverse effects. Overall patient outcomes may be improved with a decrease in
the prescription of antipsychotic medication and the use of other interventions such as
nonpharmacologic approaches. This would imply that patients are exposed to minimal
adverse effects and potential drug to drug interactions associated with antipsychotic
medications.
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This project may positively impact social change in many aspects. This project
may impact social change as the development of a CPG may potentially reduce
complications, improve outcomes and quality of life of elderly patients with dementia
who are residents in nursing homes. The goal was that this CPG can be transferred and
used in other nursing homes in the area (see Mazrou, 2013). Recognizing and using this
CPG by practitioners and prescribers alike ensures that they adhere to state and federal
regulations that govern the use of antipsychotics in the elderly. The expert panel
acknowledged that the CPG prompted them to pay closer attention to antipsychotic
medication use to decrease its use in the nursing home setting through ongoing
assessments and attempts to gradually reduce and discontinue its usage. The foreseeable
impact on social change following this project is that it will potentially reduce
complications, improve outcomes and quality of life of elderly patients with dementia
who are residents in nursing homes (Mazrou, 2013).
Summary
In elderly patients with dementia, the prescription of antipsychotic medications is
commonly prescribed for neuropsychiatric symptoms associated with the disease (Press
& Alexander, 2017). However, antipsychotic medication use in patients with dementia
has been linked to increased risk of death, CVAEs, Parkinsonism, sedation, gait
disturbance, cognitive decline, and pneumonia (Tampi et al., 2016). In today’s healthcare
sector, many providers prescribe antipsychotics for patients without adequate knowledge
of current guidelines governing the use of these medications (Centers for Medicare and
Medicaid, 2013). To address this gap-in-practice, a CPG was developed based on
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evidence from the Centers for Medicare and Medicaid and the American Psychiatric
Association. Following the development of this CPG, I presented it to an expert panel at a
nursing home, potentially to seek their consensus on its full implementation. The goal of
this project is to help address the gap in practice, increase knowledge, and decrease
prescription of antipsychotic medications while improving patient outcomes and quality
of life. Major concepts, models, frameworks, background, and context for the project are
reviewed in Section 2.
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Section 2: Background and Context
Introduction
Despite recognized adverse effects, antipsychotic medications continue to be
frequently prescribed to patients with dementia who exhibit neuropsychiatric symptoms
associated with the disease process when not necessary, increasing patient adverse
outcomes and in violation of regulatory requirements. According to Jeste and Maglione
(2013), 20% to 50% of patients with dementia are prescribed antipsychotics medications.
The FDA approved indications for antipsychotic medications for mental health
conditions, including bipolar 1 disorder, bipolar depression, schizophrenia, and
schizoaffective disorder, as well as major depressive disorder adjunct (Centers for
Medicare and Medicaid, 2013). None of the antipsychotic medications are indicated for
treating behavioral disorders in patients with dementia. Thus, polypharmacy of
psychotropic medication among patients with dementia is particularly concerning when
patients are admitted for coexisting psychiatric conditions. In fact, the FDA issued a
warning labeling antipsychotic medications as causing an increased risk of mortality
among this population (De Jong, Van der Elst & Hartholt, 2013). Aside from the risk of
increased mortality, patients with dementia who are exposed to antipsychotic medication
may encounter additional adverse effects such as cardiovascular and metabolic effects
(Tampi et al. 2016).
Promoting the safe use of medications in the elderly is of great importance as
caution needs to be exercised to minimize exposure to adverse effects. Jose (2012)
stressed the importance of developing guidelines and protocols on geriatric medication
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that focus on drug safety. The purpose of this project was to develop a CPG and present it
to an expert panel of nurse practitioners. Once developed, the CPG was presented to an
expert panel with the goal of raising awareness and empowering prescribers to potentially
change prescribing habits when it comes to this class of medication. Thus, with the DNP
project, I sought to answer the guiding practice-focused question: Will an expert panel
approve the use of a CPG on the use of antipsychotic medication in the nursing home
setting?
Concepts, Models, and Theories
Clinical practice guidelines have become the standard of practice in the healthcare
sector. It is a way of ensuring that evidence-based research is incorporated into everyday
healthcare decision making. Guidelines that shape practice have become a way of life for
healthcare professionals as it helps in bridging the gap between policy and best practice
(Kredo et al. 2016). The primary goal of CPG is to improve effectiveness and quality of
care while decreasing variation in clinical practice, cost, preventable mistakes, and
adverse events (Kredo et al. 2016). The use of evidence-based research is essential for a
CPG to be effectively implemented. This helps foster improvements in current processes
and overall clinical outcomes.
Use of Antipsychotics in Patients with Dementia
To better understand the proposed CPG, one must understand the basics about
dementia and its associated symptoms. According to the National Institute on Aging
(2017), dementia is the loss of cognitive functioning in areas of memory, language skills,
visual perception, problem solving, self-management, and one’s ability to focus and pay
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attention. According to Press and Alexander (2017), neuropsychiatric symptoms of
dementia are very common and much more troubling than cognitive symptoms. These
neuropsychiatric symptoms include agitation, aggression, delusions (particularly paranoid
delusions), hallucinations, wandering, depression, apathy, disinhibition, anxiety,
irritability, and sleep disturbances (Press & Alexander, 2017). Having a better
understanding of the proposed CPG requires fundamental knowledge of dementia and its
characteristics.
According to Sahin Cankurtaran (2014), 97% of dementia patients develop
behavioral and psychiatric symptoms during the disease. The most common and lasting
of all the symptoms is agitation, whether it be verbal or physical (Sahin Cankurtaran,
2014). For many years’ healthcare professionals have used antipsychotic medications as
first-line agents for managing nursing home patients who exhibit behaviors such as
agitation, aggression, and psychotic symptoms of delusions and hallucinations (Tampi, et
al. 2016). The use of antipsychotics is even more prevalent among patients with dementia
who exhibit behavioral and psychological symptoms associated with the disorder (Cioltan
et al. 2017). According to Cioltan et al. (2017), one in five patients in the 15,500 nursing
homes in the United States is prescribed antipsychotic medications that is deemed as
unnecessary and poses dangerous adverse risks for older patients. Finding alternatives to
managing behavioral disturbances in patients with dementia is important as antipsychotic
medication use is prevalent in this population.
Jeste and Maglione (2013) reported that prescription rates of this class of
medications varies between 20% and 50% in patients with dementia. Psychotropic
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antipsychotic medications are often used to treat the distress associated with psychotic
symptoms in this population when indications for their prescribed use for behavioral
management for patients with dementia is lacking.
Patients with Chronic Mental Illness and Dementia
According to Ribe et al. (2015), dementia and other mental health problems are
not mutually exclusive. The major difference is that primary psychiatric disorders usually
develop in youth and early adulthood while dementias are generally conditions that arise
in midlife and later life (Ribe et al. 2015). For many years, comorbid chronic conditions
which have been known as risk factors for dementia include schizophrenia and other
associated cardiac and cerebrovascular diseases (Saltz, Robinson and Woerner, 2004).
Schizophrenia is considered a serious and persistent mental illness and affects
approximately 0.25% and 0.64% of people in the United States (Zilkens, Bruce, Duke,
Splisbury, & Semmens, 2014). Characteristics of this disorder include disturbances in
perception, communication, and thought process as well as abnormal behavior (Larson,
2018). However, the hallmark of schizophrenia includes deficits in memory, attention and
visuospatial orientation (Zilkens et al. 2014). Patients with dementia also exhibit memory
deficits which puts them at risk for developing dementia later in life.
Ribe et al. (2015) conducted an 18-year longitudinal observational study
comparing the emergence of dementia in people with and without schizophrenia. The
population for this study was more than 2.8 million persons aged 50 years or older with
20,683 having schizophrenia (Ribe et al. 2015). Follow-up for this study started in
January 1995 and ended in January 2013 with analysis from January 2015 to April 2015
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(Ribe et al. 2015). During the 18 years of follow-up, 136,012 individuals, including 944
individuals with a history of schizophrenia, developed dementia (Ribe et al. 2015). After
adjusting for age, sex, and seasonality, the study concluded that schizophrenia was
associated with a higher risk (IRR, 2.13; 95% CI, 2.00-2.27) of all-cause dementia (Ribe
et al. 2015). Reviewing medications of patients with schizophrenia who later develop
dementia is crucial. This will help prescribers to determine if antipsychotic medications
are warranted based on symptomology.
In patients with affective disorders, namely depression and bipolar, symptoms are
often associated with issues with attention, executive function, and memory. These
symptoms are not only evident during the acute phase of the disease but during
remissions, particularly problems with executive function and attention (Da Silva,
Goncalves-Pereira, Xavier, & Mulkaetova-Ladinska, 2013). The aim of the study by Da
Silva et. al (2013) was to evaluate the risk of developing dementia in individuals with a
history of affective disorders. In their systematic review, 51 case-control and cohort
studies that addressed the risk of developing dementia in people with affective disorders
were included (Da Silva et al. 2013). Results of the review suggested that more frequent
and severe episodes of depression seem to increase the risk of dementia suggesting that
depression may be both a precursor and a risk factor for dementia (Da Silva et al. 2013).
According to Da Silva et al., the risk estimates for dementia in people with bipolar
disorder far exceed those with depression.
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Alternatives to Manage Behavior in Long-Term Dementia Patients
Evidence suggests moving away from medication-focused dementia care to the
use of nonpharmacologic approaches in the management of difficult behaviors associated
with the disorder (Agency for Healthcare Research and Quality [AHRQ], 2014;
Buchanan, Christenson, Ostrom & Hofman, 2007; Livingston et al., 2014).
Neuropsychiatric symptoms such as agitation and aggressive behavior not only endangers
the person with dementia but for caregivers alike. According to Buchanan et al., (2007),
approximately 50% of nursing assistants have been injured during resident assaults.
Buchanan et al. (2007) continued that a significant indicator of job-related stress and
frustration for professional caregivers is behavioral disturbances mainly agitation and
aggression. Equipping staff with the necessary skills to handle difficult behaviors among
dementia patients may help in alleviating job-related stress from behavioral disturbances.
For many years antipsychotic medications have been used as first-line
management for behavioral disturbances associated with dementia (Tampi et al. 2016).
However, patients are exposed to several adverse events such as the increased risk for
stroke, exacerbation of cognitive decline, increased risk for death, excessive sedation, and
gait disturbances with increased risk of falls (Livingston et al., 2014). Ethically, this way
of managing behavioral disturbances has been questioned by many governing agencies
for the elderly (Centers for Medicare and Medicaid, 2016). In recent years attempts to
help address the management of difficult behaviors associated with dementia have
focused on encouraging the use of nonpharmacologic interventions that are deemed
restraint-free interventions. Nonpharmacologic interventions are often grouped into
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categories based on the goal of the interventions (Labid, Mishriky and Reyad, 2018).
According to the AHRQ (2014), sensory interventions include music therapy, light
therapy, and pet therapy. Active therapy and structured activities involve dancing,
exercising, social interactions, art therapy, and outdoor walks (AHRQ, 2014).
Complementary alternative medicine, according to the AHRQ, includes aromatherapy,
reflexology, and massage. Environmental interventions include having designated
wandering areas and having natural/enhanced environments (e.g. pictures on the walls;
AHRQ, 2014). Nonpharmacologic interventions are not only aimed at preventing the
incidence of behavioral disturbances but also help in the response and reduction of the
severity and duration of episodes as well as reduce associated caregiver distress.
Holmberg (1997) initiated a structured walking program for eleven severely
demented individuals living in a dementia unit of a nursing home. Over a 1-year period,
there was a noticeable 30% reduction in aggressive behaviors on days when the walking
program was applied (Holmberg, 1997). This is a good example of research which
provides solid evidence that there are effective alternatives to the use of antipsychotic
medications.
In the study by Hicks-Moore and Robinson (2008), the goal was to assess whether
relaxing techniques such as music and massage could decrease agitation and improve the
overall quality of life in dementia patients. Forty-one patients with mild to moderate
dementia participated in the study and were randomly assigned to either a treatment or
control group. Those in the treatment group received each of three treatments involving
10-minute hand massage, favorite music, and a combination of both (Hicks-Moore and
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Robinson, 2008). The control group received no treatment (Hicks-Moore and Robinson,
2008). The Hicks-Moore and Robinson study concluded whether individually or
combined, favorite music and hand massage were effective in reducing agitation during
the intervention and 1-hour afterward. This study shows the importance of adopting nonpharmacologic interventions such as music and massage in the management of
neuropsychiatric symptoms associated with dementia.
Caregiver interventions are often focused on staff education and training (Joaquin
et al. 2018). Staff education focuses on managing behavioral disturbances by exploring
the underlying causes such as pain, incontinence, and hunger, (Joaquin et al. 2018). Other
areas to be addressed included both knowledge and skill training for managing disruptive
behaviors in the long-term care setting while limiting the administration of antipsychotic
medications. A study by Joaquin et al. (2018) evaluated the effectiveness of a dementia
education program for direct caregivers of dementia patients in a skilled nursing facility.
Of a total of twenty-nine CNAs, thirteen underwent Abilities Care Experts (ACE)
training, and sixteen were non-ACE trained. A survey was given to measure key factors
associated with quality of care, namely, knowledge, attitudes, self-efficacy, and job
satisfaction. Joaquin et al. (2018) concluded that participants who underwent ACE
training demonstrated significantly higher levels of self-perception in areas of dementia
knowledge (t (27) =3.44, p=.002), knowledge of dementia care approaches (t (26) =3.57,
p=.001), and self-efficacy (t (25) =2.40, p=.024). The study by Joaquin et al. (2018)
shows the importance of having an education program for direct staff members who work
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with dementia patients. With training, staff will have the knowledge and skills to
effectively manage behaviors associated with dementia.
Watson’s Model of Caring
Neuropsychiatric symptoms associated with dementia, primarily agitation and
aggression, have been noted to cause distress and burden for caregivers (Cheng, 2017). In
addition, approximately 50% of nursing assistants have been injured during resident
assaults (Buchanan et al. 2007). This ultimately affects the provision of care which is
very critical given that caring forms the fundamental core of nursing. Providing safe and
quality care for patients with dementia, especially those who exhibit difficult behaviors,
is of importance. Therefore, I used Watson’s model of caring in this DNP project to guide
the development of a CPG and, ultimately, to enhance the quality of care among
dementia patients. According to the Watson Caring Science Institute (2010), Watson’s
theory of human caring makes up the moral ideal of nursing which results in protection,
enhancement, and preservation of human dignity. By presenting the CPG to an expert
panel, the goal was that prescriptive practices will be impacted and other alternatives to
managing behavioral disturbances will be explored as a first resort. Once this becomes
part of practice, the preservation of human dignity as highlighted in Watson’s model of
caring, would become evident. Patients would be exposed to minimal adverse effects
associated with the use of antipsychotic medications. By improving the quality of care
dementia patients receive, their human dignity is protected, enhanced, and preserved.
Part of Watson’s caring factors is the promotion of scientific problem-solving
methods for decision making (Watson Caring Science Institute, 2010). This pertained to
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the DNP project in determining a long-term care facility’s ability to employ other
options, such as nonpharmacologic interventions as opposed to antipsychotic medication
use, when managing behaviors associated with dementia. This was evident through the
development of the CPG which evolved from evidence in the literature.
As part of the model of caring, Watson (2010) stressed the importance of
developing a helping-trusting relationship. For this project, this translates into being
honest, genuine, and transparent in all communication with the nursing home staff. The
last of Watson’s carative factors is most pertinent to this project and entails the promotion
of interpersonal teaching (Watson Caring Science Institute, 2010). By presenting the
CPG to the expert panel, the goal was to have a better understanding of the use of
antipsychotic medications, adverse events associated with them, and changing
prescribing practice to reduce their usage.
To summarize, one key component of Watson’s model of caring that relates to the
DNP practice-focused question includes the protection, enhancement, and preservation of
human dignity. Certainly, by avoiding the harmful consequences of antipsychotics in the
elderly patient with dementia, human dignity is protected, enhanced, and maintained.
Similarly, Watson’s carative factor through problem-solving and decision making is
another key component of the model that has application in the DNP project. The
problem-solving and decision making carative factor are made visible through the
prescriber’s decision making and problem-solving with regard to alternatives to the use of
antipsychotic medications. Finally, two other components of Watson’s model contribute
to the DNP project: (a) a helping-trusting relationship, and, (b) the promotion of
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interpersonal teaching. These last components are made real in the prescriber-patient
relationship, and in the prescriber’s relationship with the staff at the nursing home.
Providing dementia-related care becomes difficult when persistent and
unmanageable neuropsychiatric symptoms become problematic. Watson’s model of
caring focuses on the protection, enhancement, and preservation of human dignity. The
goal of this project aligns with that of Watson’s model of caring given that patients would
be exposed to minimal serious side effects associated with antipsychotic medications. In
this manner, the patient’s dignity is protected and preserved as their quality of life is
optimized.
Agree II and a Model for Evaluating the Evidence
According to Kredo et al. (2016), the development and implementation of CPGs
are intended to bridge current gaps in policy and best practices while improving the
effectiveness and quality of care for patients. CPGs serve as official recommendations for
screening, diagnosis, treatment, and management of specific conditions (Murad, 2017). In
this instance, the CPG pertained to the management of neuropsychiatric symptoms
associated with dementia by using non-pharmacologic interventions, ongoing
assessments of symptoms and gradual dose reductions. Kredo et al. (2016) reiterate the
importance of developing and maintaining CPGs as a way of improving and/or
standardizing clinical practices with the ultimate goal of decreasing the cost associated
with preventable mistakes and adverse events.
The Appraisal of Guidelines for Research and Evaluation (AGREE) project was
initially published in 2003 and later replaced by AGREE II in 2013 to improve reliability,
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validity, and usability of CPGs (Cruz, Fahim and Moore, 2015). The AGREE II contains
six quality domains totaling twenty-three items which guide the development of, and help
to quantify, a rating of a guideline. The domains include scope and purpose, stakeholder
involvement, rigor and development, clarity of presentation, applicability, and editorial
independence (Cruz, Fahim and Moore, 2015).
According to MacDermid et al. (2005), the AGREE II instrument may be
replicated and used for other purposes such as education and quality assurance among
others. More than one appraiser for the practice guideline is required to improve the
reliability of the AGREE instrument. For this project I established an expert panel of six
health care provider prescribers, using a 5-point Likert scale from strongly agree (1) to
strongly disagree (5) which scored for each AGREE tool item within a domain to
evaluate the CPG being developed in this project.
With this project, the Fineout-Overholt tool was used to rank and score all the
literature used in the development of the CPG and presented in section 2 (FineoutOverholt et al. 2010). A summary of these resources is presented in a literature matrix
table located in Appendix A. In the literature matrix table, the journal articles used are
ranked as to the level of evidence from I through VII that each represents using the
Fineout-Overholt tool as shown in Appendix A (Fineout-Overholt et al. 2010).
Relevance to Nursing Practice
According to Saltz et.al, 2004, it is estimated that the majority of nursing home
residents (i.e. 50%-75%) are prescribed antipsychotic medications. A small fraction of
patients prescribed antipsychotic medications are being evaluated by a mental health
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professional (Saltz et. al, 2004). While this class of medications is generally overused,
there is evidence that this could be related to the lack of psychopharmacologic training of
practitioners and misdiagnosis of conditions in this population (Saltz et. al, 2004).
Though there are regulations by the Centers for Medicare and Medicaid, Saltz et. al.
(2004) state that many prescribers and practitioners lack the awareness and have had no
training in the use of antipsychotic agents. The implementation of this clinical guideline
ensured that practitioners and prescribers received the necessary knowledge about this
class of medications. The CPG focused on not only decreasing the prescription of
antipsychotic medications but also employing the use of non-pharmacologic approaches
in managing challenging behaviors.
According to Sahin Cankurtaran (2014), non-pharmacologic interventions are
recommended and to be attempted as first-line management of behavioral disturbances.
Non-pharmacologic interventions as discussed by Sahin Cankurtaran (2014) include
music therapy, massage, touch, aromatherapy, pet therapy, physical activity, and
environmental interventions. Interventions for caregivers and staff of long-term care is
also considered to be part of non-pharmacologic interventions.
According to Labid Mishriky and Reyad (2018), there is growing evidence about
the use and effectiveness of alternative medications such as cholinesterase inhibitors,
serotonin-specific reuptake inhibitor antidepressants, and anticonvulsants in managing
behavioral and psychologic symptoms. In addition, Da Silva et al. (2013) suggest an
increased risk of dementia among patients with dementia and affective disorders such as
depression and bipolar disorder. Growing evidence about the successful nature of
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alternative methods supports a non-pharmacological approach that can be used to manage
behaviors associated with dementia and a means of reducing unnecessary psychotropic
polypharmacy (Holmberg, 1997). Sensory interventions, active therapy/structured
activity, complementary alternative medicine, environmental interventions, and caregiver
education interventions have all been found to be effective non-pharmacologic strategies
(Hicks-Moore and Robinson, 2008). Hicks-Moore and Robinson (2008) have
demonstrated that non-pharmacologic interventions are effective when managing
behavioral disturbances while promoting safety, improving outcomes and minimizing
exposure to adverse events associated with antipsychotic medications.
Taken together, the above-mentioned research represents a sample of existing
scholarly evidence fully explicated in Section 2, in support of the CPG. The current state
of practice at the DNP site has been to use antipsychotic medications in the elderly
dementia patient in spite of current evidence to the contrary. Use of non-pharmacologic
alternatives, as well as gradual dose reduction for long-term psychotic patients, are
supported in the CPG and in the scholarly evidence (Hicks-Moore and Robinson, 2008;
Holmberg, 1997; Joaquin et. al, 2018).
The goal of developing this CPG and presenting it to an expert panel in the
nursing home setting is to not only raise awareness about the detrimental effects of using
antipsychotic medications in the elderly; but also to highlight the current state and federal
laws and regulations governing the prescribing of these medications. By recognizing and
using this CPG, practitioners and prescribers alike ensure that they adhere to state and
federal regulations that govern the use of antipsychotics in the elderly as well as best
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practice supported by research evidence. Once implemented, the CPG would helpful
during state and federal nursing home surveys that tend to focus on antipsychotic
medication use in long-term care facilities. Approving and adopting the CPG would
prompt the NP and MD prescribers at the DNP site to pay closer attention to
antipsychotic medication use, anticipating decreasing its use through ongoing
assessments, the use of non-pharmacologic alternatives, and attempts to gradually reduce
and discontinue antipsychotic usage.
Local Background and Context
The intended setting for this doctoral project is a nursing facility with over 250
beds located in the northeastern part of the United States. This facility has two units
which were the focus of this project--a designated 60-bed locked psychiatric behavioral
unit and a 25-bed dementia unit. According to the director of nursing at this facility,
approximately 80% of patients have a diagnosis of dementia with many of these patients
exhibiting some form of behavioral disturbance (i.e. verbal, physical aggression,
agitation, irritability, wandering, anxiety, depression, etc.) There are approximately six
total health care providers who are prescribers for the two units; four are nurse
practitioners and two are physicians who serve as attending doctors (MDs). The nurse
practitioner group is made up of two-family nurse practitioners (FNPs) and two
psychiatric nurse practitioners (PMHNPs). Many of these residents also have a primary
diagnosis of schizophrenia, bipolar, depression, or a schizoaffective disorder with many
being on antipsychotic medications for many years of their lives. Patients with mental
health diagnoses residing on the locked behavioral unit may also have a secondary
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diagnosis of dementia. Some patients on the dementia unit may have co-occurring
psychiatric conditions (is that true), Thus, both units were focused on for this project to
increase awareness of the prevalence of the issue and the need for a change in practice in
this setting.
The complexity of the patient population in this setting dictates the need for a
CPG that encompasses state and federal recommendations. Nursing staff in the long-term
care setting rely heavily on health care providers to prescribe medications such as
antipsychotics in cases where behaviors are challenging and difficult to manage.
Therefore, developing and presenting a CPG that may impact prescribing practices in
general, and how nurse practitioners respond when nurses contact them about managing
challenging behaviors, are strategies that can positively influence practice at the site.
Role of the DNP Student
My role as a DNP student was to lead in the development of the practice guideline
and present it to an expert panel with the intention of adoption and full implementation
(although adoption and full implementation will occur out of the scope of the DNP
project). This is in accordance with the DNP Essential III (American Association of
Colleges of Nursing, 2006) which involves analyzing and addressing a gap in practice
with inventions that promote a safe, time effective, efficient and patient-centered change.
For this project I worked in collaboration with other members of the long-term care
setting, namely, the administrator, director of nursing, charge nurses, and unit managers,
to explore any current policies and current practices pertaining to the management of
behavioral disturbances among dementia patients.
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In achieving my role of developing a CPG, I performed a literature review of
existing information pertaining to current guidelines and recommendations by both state
and federal organizations. This included information on the Massachusetts Department of
Health website, information from the Centers for Medicare and Medicaid (CMS), and a
review of current guidelines by the American Psychiatric Association. Based on this
information, a CPG was developed with the focus on documentation that patients,
guardians, and proxies had been advised of risks associated with antipsychotic
medications, as well as periodic assessments to monitor side effects, the need for these
medications, and attempts to gradually reduce and discontinue medications if no longer
indicated. As a DNP student, my ultimate role was to put this information in a
PowerPoint presentation and present the information to the assembled expert panel. As
the leader for this project, my role following the presentation was to assess the expert
panels’ willingness to adopt and implement the practice guideline. This was
accomplished via a survey process to assess the impact of the presentation on knowledge
and whether prescribers approved of the use of this CPG in their practice.
Role of the Project Team
The project team consisted of the expert panel who made up the primary
stakeholders. The expert panel was made up of six prescribers for the long-term care
setting. Enlisting prescribers for this project was vital given that the goal of this project is
to potentially change prescribing habits of antipsychotic medications in the nursing home
setting. As previously mentioned, the expert panel consisted of one psychiatrist, one
medical doctor, two family nurse practitioners, and two psychiatric mental health nurse
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practitioners. The role of this project team was to participate in an educational session
whereby the author presented a PowerPoint on the use of antipsychotic medications in
long-term settings. As part of this educational session, the project team was presented
with an overview and given hard copies of the CPG for their review. Following the
presentation, the expert panel was asked to provide feedback through open-ended
discussions and a survey. In the open-ended discussion, input was sought based on an
overall impression of the antipsychotic CPG, barriers to full implementation as well as
suggested revisions and recommendations. The expert panel was asked to complete a
survey that focused on knowledge attained during the presentation.
Summary
Despite recognized adverse effects, antipsychotic medications continue to be
frequently prescribed to patients with dementia who exhibit neuropsychiatric symptoms
associated with the disease process. The research evidence presented in Section 2
provides a compelling argument for the components of the CPG, the local issues at the
DNP project setting, the role of the DNP student, and the project team. Section 3 provides
information on the sources of evidence that was used and the process of achieving
consensus on the practice guideline.
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Section 3: Collection and Analysis of Evidence
Introduction
Larson (2018) defined dementia as an overall decline in cognition related to one
or more of the cognitive domains, namely, learning and memory, language, executive
function, complex attention, perceptual-motor, and social cognition. According to Sahin
Cankurtaran (2014), 97% of dementia patients develop behavioral and psychiatric
symptoms during the disease. These behavioral problems often known as
neuropsychiatric symptoms include agitation, aggression, delusions (particularly paranoid
delusions), hallucinations, wandering, depression, apathy, disinhibition, anxiety,
irritability, and sleep disturbances (Press &Alexander, 2017).
Neuropsychiatric symptoms are often difficult not only for the person with
dementia but also for caregivers. Antipsychotic medications have long been prescribed to
patients with dementia in attempts to manage neuropsychiatric symptoms that are
associated with the disease (Tampi, et al. 2016). Jeste and Maglione (2013) reported that
prescription rates for antipsychotic medications among dementia patients vary between
20-50%. Antipsychotic medications have been linked to serious adverse effects which
include increased risk of death, CVAEs, and other worrisome side effects (Tampi et al.
2016). No antipsychotic medication is indicated for treating neuropsychiatric symptoms
in patients with dementia, but merely for true psychotic disorders such as bipolar 1
disorder, bipolar depression, schizophrenia, and schizoaffective disorder with a major
depressive disorder (Centers for Medicare and Medicaid, 2013).
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Providers and prescribers often get phone calls from caregivers who are desperate
to alleviate these psychiatric dementia symptoms. Sometimes telephone orders are given
to nurses without proper assessment of the patient’s condition or ruling out any organic
causes for their presentation. In fact, according to Saltz et al. (2004), the misuse of
antipsychotic medications is often prevalent with practitioners who lack
psychopharmacologic training. No protocol for the care of dementia patients who exhibit
neuropsychiatric symptoms in the nursing home setting of my project is available to
guide prescribing. Therefore, the purpose of this project was to develop a CPG on the use
of antipsychotic medications with the goal of potentially changing prescribing habits in
the nursing home setting.
In Section 3, there is a full description of the practice-focused question and a
review of the sources of evidence used to develop the project. In addition, there is a
detailed overview of the procedures proposed to collect evidence to evaluate the potential
implementation of the CPG at the site. Finally, Section 3 includes information regarding
the analysis and synthesis of the data and a summary.
Practice-Focused Question
The practice-focused question for this project was Will an expert panel approve
the use of a CPG on the use of antipsychotic medication in the nursing home setting? To
answer this question, a CPG was developed for prescribers and practitioners who care for
patients with dementia at the project site, a long-term care nursing facility. The developed
CPG was presented to an expert panel after which a qualitative survey was given to
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ascertain whether providers gained knowledge and were likely to adopt the CPG as part
of their every-day practice.
Sources of Evidence
Most of the evidence gathered for this project emerged from databases which
included CINAHL, MEDLINE, OVID, Google Scholar, PubMed, and UpToDate. This
led to journals generated through various organizations such as Current Alzheimer’s
Research, Journal of Nursing Education, The American Journal of Psychiatry,
Alzheimer’s & Dementia, (which is the primary journal of the Alzheimer’s Association)
Journal of Psychiatry, and BMC Geriatrics among others. Key search terms used to
search these databases included, but were not limited to, dementia, behavioral symptoms,
agitation and aggression in dementia, antipsychotic medication use in dementia, and
antipsychotic medications in nursing homes. Content for the CPG was generated by
reviewing information from the Centers for Medicare and Medicaid as well as current
practice guidelines by the American Psychiatric Association. A summary of the relevant
literature included in Section 2 and used to develop the CPG is presented in a literature
matrix (see Appendix A) with an evaluation of the levels of evidence according to the
Fineout-Overholt hierarchy of evidence tool (Fineout-Overholt et. al., 2010).
Evidence Generated for the Doctoral Project
The DNP project’s focus is on a CPG developed for the use of antipsychotic
medication use in patients with dementia residing long-term setting (i.e. nursing homes,
assisted living, group homes, etc.). In this instance the CPG pertains to the management
of neuropsychiatric symptoms associated with dementia by using nonpharmacologic
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interventions, ongoing assessments of symptoms, and gradual dose reductions. The
development of the CPG was based on the review of existing evidence from the
literature, the professional guidance from CMS (2016), and the American Psychiatric
Association. The CPG was presented to the expert panel in the form of an algorithm
which provides step by step directions for what should be done when a patient exhibits
neuropsychiatric symptoms (see Figure 1).
For nurses and staff, nonpharmacologic interventions have to be trialed and
documented as either effective or ineffective before calling the prescriber. For providers
and prescribers, the CPG highlights assessment of any underlying organic causes of
behaviors such as unmet physical needs, psychological needs, environmental causes and/
or psychiatric causes. To help rule out organic causes, the guideline includes guidance on
the importance of obtaining lab work, ruling out polypharmacy, and double-checking on
the use of nonpharmacologic strategies by the nursing staff. As part of the CPG,
providers and prescribers must initiate gradual dose reduction for patients who are on
antipsychotics or have been due to a history of neuropsychiatric symptoms for over one
year.
Participants. The CPG was presented to an expert panel made up of six
providers, all prescribers, who have been working in the long-term care setting for over
five years. The makeup of the six expert panelists includes one psychiatrist, one medical
doctor, two family nurse practitioners, and two psychiatric mental health nurse
practitioners. The nurse practitioners are all masters prepared who are licensed to
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Figure 1. CPG for antipsychotic use in long-term care.
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prescribe medications in the long-term care setting. They are often the front-line to phone
calls and messages about patients exhibiting neuropsychiatric symptoms. The psychiatrist
and medical doctor involved act as supervisors for this group of nurse practitioners as
required by Massachusetts state law. Nursing staff contact providers seek and typically
obtain a medication order when patients present with behavioral disturbances, leading to
overuse of chemical restraints for patients. The CPG developed for this project had the
potential of changing this culture of practice as providers were likely to use evidencebased practice protocol, to begin with, assessment (e.g., ask questions about triggers for
behaviors and the use of non-pharmacologic interventions) prior to prescribing
antipsychotic medication. The other gap in practice was that patients with a history of a
primary psychotic disorder superimposed with the diagnosis of dementia were likely on
antipsychotic medications which might have been primarily used for their psychiatric
disorder. With the CPG the goal was that providers would pay close attention to patient
medications and initiate gradual dose reductions especially when patients are no longer
exhibiting behaviors consistent with their primary psychiatric diagnosis of dementia.
Procedures. Following the development of the CPG, I enlisted the expert panel
by inviting them to take part in an expert panelist questionnaire for this DNP project. A
PowerPoint following a set curriculum was developed (see Appendix B) and presented to
the expert panel. The PowerPoint presentation highlights the importance of changing
prescribing practices to reflect the current evidence in the literature. The expert panel was
given a printed version of the CPG that was reviewed during the presentation. As part of
the segment, there was an opportunity for the panel discussion, especially regarding any
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concerns and anticipated obstacles that would impede the adherence and compliance with
the CPG. The three initial questions of the survey were open-ended in nature to generate
conversation about the CPG (Appendix C). The remainder of the questions were
developed on a 5-point Likert scale to measure knowledge of psychotropic medication
use, attitudes related to the evidence presented, and the potential of adopting this CPG as
part of everyday practice.
Protections. Attempts were made to ensure the ethical protection of the expert
panel. I sought permission from the long-term setting and requested documentation to
seek an exemption status from the Institutional Review Board (IRB) and consent to
present the data from the CPG to the expert panel. Upon approval of this proposal, I
applied to Walden University IRB. I received approval from the Walden University IRB
to conduct the doctoral project using the Clinical Practice Guideline Manual as a guide;
my IRB approval number is 06-11-19-0756892.
Analysis and Synthesis
The purpose of the qualitative assessment was to have an open dialogue in regard
to potential barriers that may impede the adoption of the CPG. This allowed for insight
into current perceptions surrounding the use of antipsychotic medication in the nursing
home setting. A qualitative data analysis method was used to analyze the data collected
from the expert panel. A narrative analysis approach was used to present the data from
notes taken during the presentation. Qualitative data from the post-presentation
discussion was summarized thematically and presented in Section 4. Quantitative data
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was gathered via the Likert scale, and the information was summarized using descriptive
statistics; this is also presented in Section 4.
Summary
In summary, the information gathered for this project was reliable and based on
evidenced-based practice data in the management of neuropsychiatric symptoms
associated with dementia. The evidenced-based information for this CPG was presented
in an algorithm that was clear and easy to follow. With this CPG the focus was not only
on the exhibition of neuropsychiatric symptoms but also the use of non-pharmacologic
interventions, the need for ongoing assessment to rule out any organic causes, and the
initiation of gradual medication changes.
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Section 4: Findings and Recommendations
Introduction
Dementia is an overall decline in cognition relating to one or more areas of
learning and memory, language, executive function, complex attention, perceptual-motor,
social cognition (Larson, 2018). Most dementia patients (97%) develop behavioral and
psychiatric symptoms during the illness (Larson, 2018). These symptoms include
agitation, aggression, delusions, hallucinations, depression, anxiety, disinhibition, and
sleep disturbances, among others (Press &Alexander, 2017). Neuropsychiatric symptoms
are not only disturbing for the patient, but also for the caregivers. Antipsychotic
medications have been used for many years as first-line agents in the management of
neuropsychiatric symptoms associated with dementia (Sahin Cankurtaran, 2014)). The
gap in practice was that prescribers were using this class of medication without adequate
knowledge of current guidelines governing their use in dementia patients.
The practice-focused question was: Will an expert panel approve the use of a
CPG on the use of antipsychotic medication in the nursing home setting? Therefore, the
purpose of this evidence-based project was to develop a CPG aimed at raising awareness
about current issues governing the use of antipsychotic medications in dementia patients
as well as promoting the use of nonpharmacologic interventions. The CPG was then
presented to an expert panel of six prescribers.
The sources of evidence used to create the CPG included current
recommendations from the Centers for Medicare and Medicaid and the American
Psychiatric Association. A literature review was done via CINAHL, MEDLINE, OVID,
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Google Scholar, PubMed, and UpToDate. The Fineout-Overholt ranking tool was used in
ranking the level of evidence for this project. Using this ranking tool assured that best
quality of evidence was used in creating the CPG.
Findings and Implications
A clinical practice guideline to reduce antipsychotic medication use among longterm care patients while enhancing the use of nonpharmacologic interventions was a
necessary adjunct to care in the DNP practice setting. This is due to recent initiatives by
many state and federal agencies such as the Centers for Medicare and Medicaid targeting
the overall reduction of antipsychotic medication use (Centers for Medicare and
Medicaid, 2013). The CPG provided step by step directions and help to guide prescribers
in cases where a patient exhibits behavioral disturbance and requires immediate
management. CPGs are necessary for the overall provision of quality care while
decreasing preventable mistakes and adverse events (Kredo et al. 2016). The primary
goal of presenting this CPG to an expert panel of providers was to increase knowledge
about current guidelines governing the use of antipsychotic medications. Thus, the expert
panel was presented with up to date, evidence-based nonpharmacologic interventions that
serve as alternatives to managing behavioral disturbances.
The CPG was presented to an expert panel of six prescribers via a PowerPoint
presentation. After the presentation time was allotted for an open discussion. Overall, the
expert panel was impressed with the CPG and thought of it as a great tool. Some of the
foreseeable barriers to full implementation of the CPG as discussed included the lack of
objective tracking of behaviors, the use of nonpharmacologic interventions, and the
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effectiveness. A major concern raised during this open dialogue session was that nursing
staff will need to be fully educated about this guideline and to ensure that all elements
(i.e. behavioral tracking) would be in place before providers are called for an
antipsychotic medication order. The reasoning behind this was that some nurses tend to
call providers out of panic without attempting nonpharmacologic interventions and in the
quest to get medications as a primary source of managing difficult behaviors. It was also
suggested during this session that staff training on the successful use of
nonpharmacologic interventions will be critical to ensure that not only are staff
comfortable, but also are using the interventions correctly. Five of the expert panelists
suggested holding off on implementing the CPG until a behavioral tracking form has
been developed and fully implemented. However, aspects of the CPG that were suggested
to be implemented immediately were situations requiring NP/MD/PA assessment of the
behavioral disturbance (i.e. ruling out organic causes for the behavior). Another area
deemed appropriate to implement right away, regardless of a behavioral log, was the
initiation of gradual dose reductions (GDRs) with patients already prescribed
antipsychotic medications for chronic persistent mental illnesses. A strong suggestion
during this post-presentation discussion was to enlist the support of the nursing
department to review medication administration records (MAR) and to start discontinuing
as needed (PRN) antipsychotic medications that have not been used in the last 2-6
months. This was a great suggestion as it will help eliminate PRN antipsychotic
medications that are currently not being used. All six expert panelists gave their full
support to implement the CPG.
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Following the post-presentation discussion, the expert panelists were encouraged
to provide feedback by completing an anonymous survey. The survey consisted of nine
questions to help assess the expert panel’s overall understanding of dementia,
psychopharmacology, current guidelines, and nonpharmacologic interventions used
(Appendix C). Each item on the survey was rated on a 5-point scale ranging from 1
‘strongly agree’ to 5 ‘strongly disagree’ with three midpoints (4 ‘disagree’, 3 ‘neutral’
and 2 ‘agree’). The scale used was to measure the extent to which each criterion was
fulfilled. All six expert panelists filled out a survey making the response rate 100%. The
results of the survey were tallied (see Table 1).
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Table 1
Survey results from the expert panel
Antipsychotic and
Presentation Questions:

1. The objectives of the
presentation were
clearly defined.

# of
responses
n
%
6 100%

5
Strongly
disagree
n
%

4
Disagree
n

%

n

3
Neutral

2
Agree

%

n
%
2 33.3%

1
Strongly
agree
n
%
4 66.6%

2. The topics covered
were relevant to my
current practice,

6 100%

6 100%

3. The CPG (CPG) was
well organized and easy
to follow.

6 100%

6 100%

4. I have a better
understanding of
dementia disorder.

6 100%

2 33.3%

3 50%

1 17%

5. I have a better
understanding of
neuropsychiatric
symptoms associated
with dementia.

6 100%

1

4 66.6%

1 17%

6. I have a better
understanding of the
adverse effects of
antipsychotic
medications.

6 100%

1 = 17%

3 50%

2 33.3%

7. I have a better
understanding of nonpharmacologic
interventions in the
management of
behavioral disturbances.

6 100%

3 50%

3 50%

8. I will apply the
knowledge learned from
this presentation in my
everyday practice.

6 100%

3 50%

3 50%

9. The presentation met
my expectations

6 100%

3 50%

3 50%

17%
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For the first item of the survey, about 67% of respondents strongly agreed that
objectives were clearly defined while 33% scored it a 2, ‘agree’. For the second question
on the survey, all expert panelist (i.e. 100%) strongly agreed (i.e. 1) that the topics
covered were relevant to their current practice. The next item pertained to the
organization of the CPG which all expert panelists (i.e. 100%) strongly agreed (i.e. 1) that
the CPG was easy to follow. The fourth question pertained to whether expert panelists
had a better understanding of the CPG. A third (33%) of the expert panelists felt neural
(i.e. 2), and 50% marked agreed (i.e. 3) while 17% (i.e. 1 panelist) marked strongly
agreed. In terms of a better understanding of neuropsychiatric symptoms of dementia,
17% (i.e. 1 expert panelist) felt neutral. Most of the experts (66%; i.e. 4 of the panelists)
strongly agreed and 17% (i.e. 1 expert panelist) agreed. Only 17% of the panelists felt
neutral about having a better understanding of the adverse effects of antipsychotic
medications while 50% (3 of the expert panelists) agreed and 33% marked strongly
agreed. The seventh item on the survey pertained to whether the expert panel had a better
understanding of nonpharmacologic interventions in the management of behavioral
disturbances. Half of the respondents strongly agreed that they had a better understanding
of this while the other half marked agreed, achieving 100% agreement on this item. Half
of the panel agreed to apply the knowledge learned from the presentation in their
everyday practice while the other 50% strongly agreed to do this, again achieving a 100%
agreement on this important point. Overall, all the expert panelists agreed that the
presentation met their expectations.
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The feedback from both the open discussion and survey segments of the
presentation helped in shedding insight on the practicality of this CPG. The conclusion
from the expert panel’s review of the CPG suggests that with a tool to track behaviors
and effectiveness of non-pharmacologic interventions, the CPG can be successfully
implemented. The care and management of neuropsychiatric symptoms of dementia can
be challenging for both caregivers and prescribers alike. Promoting the safe use of
medications while fostering the use of non-pharmacologic interventions is critical in the
successful management of neuropsychiatric/behavioral symptoms. Jose (2012) stressed
the importance of developing guidelines and protocols on geriatric medication that
focuses on drug safety.
Thus, there were two themes that emerged from the qualitative debriefing which
were reinforced in the quantitative survey. The first theme is one of overall acceptance of
the CPG and a willingness to implement it in the BH setting. The NPs and MDs that
made up the expert panel agreed that the CPG has value and merit in the long-term BH
setting; in addition, the panel acknowledged the harmful effects of antipsychotic
medications on the patient with dementia, even if the patient has had many years of
antipsychotic medication management. The second theme that emerged was one of
practicality. That is, the panel were mindful of the need to reduce antipsychotic use, but
concerned that the nursing staff would require education on the CPG and strategies to
manage assertive and aggressive behaviors among the patient population using nonpharmacologic means. This theme of practicality introduces the need for follow up
recommendations.
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The ability of nursing staff and prescribers to accurately track and safely manage
difficult behaviors associated with dementia is crucial in improving overall health
outcomes. The CPG translates into a positive social change as the CPG stresses the
importance of employing alternatives such as safe non-pharmacologic interventions as a
strategy to reduce the use of antipsychotic medications. With successful training of staff
on the use of non-pharmacologic interventions and the implementation of a behavioral
log, the CPG can be fully adopted which will impact quality measures regarding the use
of antipsychotic medications in long term care settings.
Recommendations
The primary focus for this project was to close the gap in the practice of
prescribers using antipsychotic medications to manage neuropsychiatric symptoms
without proper assessment of the residents’ status. Part of the project goal was to
highlight the use of non-pharmacological interventions as a way of addressing behavioral
disturbances. This will require intensive staff training to ensure that staff members are
knowledgeable and comfortable applying non-pharmacologic interventions. Part of the
CPG requires that nursing staff attempt and document the trial and effectiveness of nonpharmacologic interventions. Ensuring that there is a formal tool for this will help track
patterns of behaviors, the effectiveness of interventions, and help prescribers determine
when medication is absolutely warranted. It is difficult for the prescriber to make clinical
decisions without knowledge of whether non-pharmacologic interventions have been
attempted and whether they were effective. The actual implementation of this CPG
should be considered given that positive feedback was received from the expert panel.
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Full implementation would be in the form of adopting the CPG and making it part of the
facility’s medication administration policy for providers. This, however, cannot be
completed without the existence of a behavioral log and training of staff as it is an
integral part of the CPG. A full implementation and policy change will ensure that the
facility is adherent to both state and federal regulations governing the use of
antipsychotic medications in long-term care settings. Following full implementation, a
Quality Improvement (QI) initiative is needed, wherein prescriptions of antipsychotic
medications for each patient with dementia are closely monitored over a 6-month to 12month period. Follow-up meetings will be planned in the future with prescribers using
results of the QI data to gauge adherence to the CPG and its impact on clinical practice.
Strengths and Limitations of the Project
This project presented several strengths and limitations. The strengths of the
project include the use of evidence-based data and recommendations by the Centers for
Medicare and Medicaid as well as the America Psychiatric Association in the
development of the CPG. A focus on the use of antipsychotic medications in long-term
care setting is of absolute importance given that recent efforts by state and federal
agencies target this subject. The CPG not only focuses on reducing the likelihood of
prescribing antipsychotic medications, but also includes patients already prescribed
antipsychotic medications through the use of GDR. All members of the expert panel for
the targeted facility were present for the presentation and showed enthusiasm and
commitment to learn about current regulations governing the use of antipsychotic
medications and agreed to full implementation after the behavior log and the education
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for the frontline nursing staff are completed. There was an overall positive response in
terms of the need for such a CPG. The expert panel were proactive in making next-step
suggestions such as the identification of the need for a behavioral log. The lack of a
behavioral log which serves as a critical step of the CPG hinders full implementation and
adoption of the CPG.
The limitations involved with this project include the time that prescribers had to
take out their busy schedules to attend this presentation. Coordination with these busy
providers’ coverage schedules was a bit challenging, but was finally resolved. Another
limitation to this project was that it only targeted prescribers and not the nursing staff
who will be responsible for implementing non-pharmacologic interventions. The lack of a
formal method of documenting a trial and effectiveness of non-pharmacologic
interventions at the time of this project also posed a limitation. Finally, the sample size of
a 6-member expert panel was relatively small for this project. The CPG may be expanded
to providers at other long-term care settings, especially when addressing the problem of
reducing antipsychotic medication use.
Summary
The development of this CPG was an effective way of ensuring that basic
standards to antipsychotic medication use in long-term care settings was established and
in accordance with current state and federal guidelines. Presenting the CPG guideline to
the expert panel alongside a post-presentation discussion and survey revealed the overall
willingness to adopt it in everyday practice. A full implementation of this CPG will
require a medication administration policy change via a QI initiative. Recommendations
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from the expert panel suggest that full implementation and adoption of the CPG would be
dependent on having a concrete behavioral tracking tool and educating frontline nursing
staff. In the future, ensuring a follow-up as part of a QI process to ascertain full
implementation and prescribers comfort level would be ideal.
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Section 5: Dissemination Plan
The CPG was disseminated to practice through a formal presentation of
information to the expert panel. The expert panel was made up of two medical doctors,
two family nurse practitioners, and two psychiatric nurse practitioners. The CPG will
further be disseminated throughout the organization via ongoing formal presentations to
ensure that it is available to the nursing education department, nurse managers, and other
administrative teams responsible for issues governing patient care. In doing so, the goal is
that a behavioral log will be developed and aspects of dementia training pertaining to
managing difficult behaviors will be revamped.
Additional plans to help disseminate this CPG would be seeking permission to
present it to other prescribers in the area during quarterly prescribers’ meetings. This
CPG is pertinent to other prescribers outside the long-term setting especially those in
acute hospital and outpatient settings. To reach a broader nursing audience, I will submit
a manuscript for publication to a peer-reviewed nursing journal.
Analysis of Self
The complexity of the current healthcare system requires driving forces for
policies and best practices. Embarking on this DNP journey was to advance my nursing
role in areas of clinical practice and leadership. When I first started the DNP program, I
had many projects in mind, but quickly learned that I had to pick one that was relevant to
my clinical practice. As the project progressed, I found that I was gaining knowledge on
all different levels including researching skills, critiquing evidence, and organizational
skills. Though the project seemed straight forward in the beginning, it became apparent
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that connecting research and practice was critical. This was difficult to achieve in the
beginning as an already practicing clinician. As the project progressed, I found myself
questioning aspects of clinical practice and seeking opportunities to initiate change. As
part of my long-term professional goals, this project has motivated me to work with the
education department at the long-term facility to design and develop a behavioral log that
meets the needs of patients. Completing this project brought a sense of both personal and
professional fulfillment.
The greatest challenge for me was adhering to the timeline of events and the lack
of time management at various stages, either due to work or to family constraints. To
help resolve these issues, I had to dedicate specific times during the day to work on and
to complete milestones for the project. The insight gained from this DNP project journey
was the amount of time it took to develop all aspects of the project as well as the amount
of research needed. Overall, the experience was a positive one, especially when it came
to acquiring knowledge about the elderly population and matters that affect their health
outcomes.
Summary
The purpose of this evidence-based project was to develop a CPG that aimed at
raising awareness about current issues governing the use of antipsychotic medications in
dementia patients as well as promoting the use of nonpharmacologic interventions. The
CPG was developed through a rigorous review of the literature including those from the
Centers of Medicare and Medicaid as well as the American Psychiatric Association. The
CPG was presented to an expert panel who expressed positive feedback in areas of the
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topic’s relevance to practice, a better understanding of dementia disorder,
neuropsychiatric symptoms, the use of nonpharmacologic interventions, and providing
full support to implement the CPG.
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Expert opinion
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Note: Key for ranking the level of evidence used in Section 2 from FineoutOverholt, Melnyk & Williamson (2010)
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Appendix B: Presentation Overview for Expert Panel
Learning Outcome(s): Apply the Antipsychotic Drug CPG in the BH/Long Term Care Setting
Nursing Professional Development Goal: Improved knowledge of the harmful effects of
Antipsychotic Drugs and overview of the CPG
Patient Outcome: More patients with lesser amounts of Antipsychotic Drug use.
Organizational Outcome: Improved Star ratings with Antipsychotic Drugs measure
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slide
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method/learner
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and Evaluation
method

Dementia
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Şahin Cankurtaran E. (2014). Management of
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Jeste, D. V., & Maglione, J. E. (2013). Atypical
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358. http://doi.org/10.2217/cer.13.33
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change
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Centers for Medicare and Medicaid. (2013).
Atypical antipsychotic medications: use in
adults. Retrieved from
https://www.cms.gov/medicare-medicaidcoordination/fraud-prevention/medicaidintegrity-education/pharmacy-educationmaterials/downloads/atyp-antipsych-adultfactsheet.pdf
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Current trends
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Saltz, B. L., Robinson, D. G., & Woerner, M. G.
(2004). Recognizing and managing antipsychotic
drug treatment side effects in the elderly.
Primary care companion to the Journal of
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Purpose of Project
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DNP paper section 1 Purpose statement
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Centers for Medicare and Medicaid. (2013).
Atypical antipsychotic medications: use in
adults. Retrieved from
https://www.cms.gov/medicare-medicaidcoordination/fraud-prevention/medicaidintegrity-education/pharmacy-educationmaterials/downloads/atyp-antipsych-adultfactsheet.pdf
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Alternative to
managing
behaviors in
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settings
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Buchanan, J. A., Christenson, A. M., Ostrom, C.,
& Hofman, N. (2007). Non-pharmacological
interventions for aggression in persons with
dementia: A review of the literature. The
Behavior Analyst Today, 8(4), 413-425.

PowerPoint
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Hicks-Moore S.L. and Robinson, B.A. (2008).
Favorite music and hand massage: Two
interventions to decrease agitation in residents
with dementia. SAGE Journals. Retrieved from
https://doi.org/10.1177%2F1471301207085369

PowerPoint

Caregiver
Training.
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Joaquin, C, D’Amato, M., Perez, A. Villarina, A.
L., & Miller, S.E. (2018). Evaluating the
effectiveness of a formal dementia training
program; abilities care experts. Retrieved from
https://scholar.dominican.edu/masters-theses/297

PowerPoint

Presentation of
CPG

10”
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Discussion

Open discussion
about impressions
of CPG, potential
barriers to
adopting it and
suggestions about
implementation
Survey questions

30”

Centers for Medicare and Medicaid. (2016).
State operations manual (SOM) surveyor
guidance revisions related to psychosocial harm
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Appendix C: Data Collection from the Expert Panel Regarding the CPG
Round 1 Questions:
What are your impressions regarding the Antipsychotic CPG?
What barriers do you see to full implementation and reduction of the use of
antipsychotics in our setting?
Are there any revisions that you would recommend to overcome the obstacles in our
path to success?
Round 2 Questions:
What timeline would you suggest for implementation? What tools would you like to
see accompany the CPG rollout?
Are there any other implementation concerns that should be considered? If so, please
elaborate.
Round 3 Questions:
Do I have your full support to implement the CPG as of May 2019?
Antipsychotic and Presentation Questions
Following this presentation, please rate your agreement from 1 (strongly agree) to 5
(strongly disagree).
1. The objectives of the presentation were clearly defined.
Strongly disagree 5 4 3 2 1 Strongly agree
2. The topics covered were relevant to my current practice.
Strongly disagree 5 4 3 2 1 Strongly agree
3. The CPG (CPG) was well organized and easy to follow.
Strongly disagree 5 4 3 2 1 Strongly agree
4. I have a better understanding of dementia disorder.
Strongly disagree 5 4 3 2 1 Strongly agree
5. I have a better understanding of neuropsychiatric symptoms associated with
dementia.
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Strongly disagree

5

4

3

2

1

Strongly agree

6. I have a better understanding of the adverse effects of antipsychotic medications.
Strongly disagree 5 4 3 2 1 Strongly agree
7. I have a better understanding of non-pharmacologic interventions in the
management of behavioral disturbances.
Strongly disagree 5 4 3 2 1 Strongly agree
8. I will apply the knowledge learned from this presentation in my everyday
practice.
Strongly disagree 5 4 3 2 1 Strongly agree
9. The presentation met my expectations
Strongly disagree 5 4 3 2 1

Strongly agree

